Placebo News and Research

RSS

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

11 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

11 Oct 2010

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.

11 Oct 2010

Obesity treatments falter, but researchers announce gene links

The Wall Street Journal: "An international research consortium says it has identified 18 new gene sites linked to obesity and 13 others associated with how fat is distributed in the body, advances that shed new light on the complex biology underlying one of the world's most pressing public-health problems. The findings are based on studies involving nearly 250,000 people, making the effort the largest so far to unravel the genetic basis of common human traits, researchers said.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

11 Oct 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

$Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients$

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

A surgical technique appears to offer quick and effective relief for debilitating spinal fractures often suffered by patients with metastatic cancer, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan.

11 Oct 2010

Combination of MET and erlotinib delays lung cancer progression: Study

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the penis that can cause the penis to curve during erection, often interfering with or preventing intercourse and resulting in psychological distress or bother for the patient.

11 Oct 2010

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.

11 Oct 2010

Weight loss pill off shelves due to heart attack risk

Final verdict on a popular weight loss drug Reductil is to be delivered today. It is being debated whether the pill should be taken off the shelves in Australia and New Zealand. The drug Sibutramine sold as Reductil is linked to increased risk of heart attacks.

10 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Placebo News and Research

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Abbott presents data from 4 briakinumab pivotal studies in psoriasis

Obesity treatments falter, but researchers announce gene links

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Genentech initiates GDC-0449 Phase II clinical trial in BCC patients

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Balloon kyphoplasty offers effective relief for debilitating spinal fractures suffered by metastatic cancer patients

Combination of MET and erlotinib delays lung cancer progression: Study

FDA issues CRL for AZ-004 NDA application

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

Weight loss pill off shelves due to heart attack risk

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Abiraterone Phase III clinical data to be presented at ESMO meeting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News